PMCB

PharmaCyte Biotech, Inc.
CAPPED RATING

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

PharmaCyte Biotech, Inc. (PMCB) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (D). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
C
Factor Score 2.4 / 5.0
Momentum
D
Factor Score 1.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -17.6
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -35.2%
Price Return 12M -58.7%
Catalyst Signal 0.00
Market Cap $3.8M
TTM Revenue N/A
Price / Sales N/A
ROE -44.0%

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C+ (2.5) C+ (2.5) C (2.4) D (1.3) C+ (2.6) C (2.3)
2026-11-07 C+ (2.5) C+ (2.5) C (2.4) D (1.4) C+ (2.7) C (2.3)
2026-10-31 C+ (2.5) C+ (2.5) C (2.5) D- (1.1) C+ (2.7) C (2.3)
2026-10-24 C+ (2.5) C+ (2.5) C (2.5) D (1.3) C+ (2.6) C (2.3)
2026-10-17 C+ (2.5) C+ (2.5) C (2.5) D- (1.1) C+ (2.6) C (2.2)
Page 1 of 4